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Psychiatric disorders are leading causes of disability globally,
surpassing that attributed to more physical disorders. Worldwide
prevalence rates for the five major psychiatric disorders range
from 0.2% for attention-deficit hyperactivity disorder (ADHD)
to 5.7% for major depressive disorder (MDD), with schizo-
phrenia, autism spectrum disorder (ASD) and bipolar disorder
showing intermediate prevalence.1 Although these disorders are
classified into distinct disorder categories, they show overlap in
symptomatology and shared genetic risk in family studies, as well
as comorbidity in individuals and families.2 For example, 41% of
patients with ASD were found to have a comorbid disorder,
including ADHD.3 In addition, family studies show that relatives
of probands with bipolar disorder show an increased risk for both
bipolar disorder and schizophrenia.4 This could indicate common
aetiological pathways for some psychiatric disorders and studying
them jointly could lead to new insights.
Twin study heritability estimates for psychiatric disorders are
moderate for MDD (~40%) and high (80–90%) for ADHD, ASD
and schizophrenia, indicating a significant genetic component in
their aetiology.5–7 Large genome-wide studies have now started
to reveal risk variants for individual disorders but an outstanding
question is whether genetic risk factors or polygenic risk scores are
specific to particular disorders, or shared. For instance, certain
copy number variations (CNVs) are overrepresented in both
patients with schizophrenia and those with ASD.8,9 Additionally,
calcium-channel activity genes have been shown to have shared
involvement in ASD, schizophrenia and bipolar disorder, whereas
polygenic risk analysis showed strong overlap of genome-wide risk
between bipolar disorder, MDD and schizophrenia, and moderate
overlap between ASD and schizophrenia.10 In another sample,
high sharing was seen between bipolar disorder and schizophrenia,
with moderate overlap between MDD and schizophrenia, bipolar
disorder and ADHD and low, but significant, overlap between
schizophrenia and ASD.11 These results suggest that some shared
molecular genetic factors underlie a significant proportion of
the risk for development of several psychiatric disorders. To date,
however, it is not known whether these genomic overlaps are
reflected in overlapping patterns of gene expression in tissues. In
this study we therefore explored whole blood gene expression
across adult and childhood ADHD, ASD, MDD and healthy
controls, using weighted gene co-expression analysis to search
for patterns of correlated gene expression between disorders as
well as disorder-specific gene expression signatures. In addition,
we generate polygenic risk scores to assess overlap between
disorders on a genome-wide genetic-risk level. We next investigate
whether differences in polygenic risk scores are reflected in
disorder-related gene expression profiles and whether they can
be used to tease apart genetic and environmental influences on
gene expression.
Method
Participants
Participants were from four different projects and included
individuals affected with adult ADHD, childhood ADHD, MDD,
ASD, childhood dual diagnosis ADHD–ASD and healthy
controls (Table 1). Because of the age difference and its possible
confounding effect on gene expression within the ADHD
diagnostic group we decided to split the ADHD samples into a
childhood (mean age 10 years) and adult (mean age 32 years)
ADHD groups. Participant characteristics and inclusion/exclusion
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Background
Recent studies point to overlap between neuropsychiatric
disorders in symptomatology and genetic aetiology.
Aims
To systematically investigate genomics overlap between
childhood and adult attention-deficit hyperactivity disorder
(ADHD), autism spectrum disorder (ASD) and major
depressive disorder (MDD).
Method
Analysis of whole-genome blood gene expression and
genetic risk scores of 318 individuals. Participants included
individuals affected with adult ADHD (n=93), childhood ADHD
(n=17), MDD (n=63), ASD (n=51), childhood dual diagnosis
of ADHD–ASD (n=16) and healthy controls (n=78).
Results
Weighted gene co-expression analysis results reveal
disorder-specific signatures for childhood ADHD and MDD,
and also highlight two immune-related gene co-expression
modules correlating inversely with MDD and adult ADHD
disease status. We find no significant relationship between
polygenic risk scores and gene expression signatures.
Conclusions
Our results reveal disorder overlap and specificity at the
genetic and gene expression level. They suggest new
pathways contributing to distinct pathophysiology in
psychiatric disorders and shed light on potential shared
genomic risk factors.
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criteria used by each project are included in online supplement
DS1. Briefly, we included: (a) 63 people with MDD and 57
controls from the Depression Case–Control (DeCC) study, a large
case–control study that recruited unrelated patients from three
clinical sites in the UK; (b) 93 adults with ADHD attending a
National adult ADHD out-patient clinic in London, UK; (c) 16
individuals with ASD–ADHD, 7 with ASD, 17 with childhood
ADHD and 7 controls from the Biomarkers for Childhood
Neuropsychiatric Disorders (BioNed) project; and (d) 44 people
with ASD and 14 controls from the Autism Interventions (AIMS)
project. The following phenotypic information was available
within each project and subsequently used for the current cross-
disorder analyses: age, gender, diagnosis, date of collection,
ethnicity, psychoactive medication use and, for all projects except
DeCC, comorbidity of other psychiatric disorders (another
psychiatric diagnosis was an exclusion criterion in the DeCC
study). Each project has ethical approval and full informed
consent for each participant (details in online supplement DS1).
Whole blood samples were collected using PAXgene tubes for
RNA and EDTA for DNA. All RNA samples were processed within
one batch to generate whole-genome gene expression data.
Gene expression data preprocessing
Whole-genome gene expression data of a total of 424 individuals
were generated using the Illumina HT-12.v4 BeadChips at the
SGDP/BRC BioResource Illumina core lab according to the
manufacturer’s protocol. We rigorously quality controlled and
preprocessed the data using a standard pipeline (https://github.
com/snewhouse/BRC_MH_Bioinformatics), excluding sample
and probe outliers, after which robust spline normalisation and
log2 transformation were applied.12 After excluding samples based
on low-quality expression profiles we included only participants
with full phenotype data (age, gender, diagnosis, date of
collection, ethnicity, psychoactive medication use per individual,
and RNA integrity number (RIN) and RNA concentration per
sample). This left 318 participants and 5638 probes for analysis
(Table 1). To minimise project collection and sample handling
batch effects, the data were corrected for three unknown variables
captured by the SVA R package13 using a linear model. Surrogate
variable (SV)1 was not correlated to known covariates, but
SV2 and SV3 were highly correlated to cell proportion estimates
by the CellMix package:14 SV2 (neutrophils r=70.45,
P= 4.560717, monocytes r=0.42, P= 1.2610714); SV3
(neutrophils r=70.45, P=4.4610717, lymphocytes r= 0.41,
P= 2.4610714). No correlation of surrogate variables or principal
components was found with self-reported ethnicity (n=29, 9% of
participants reported ethnicity other than White).
Weighted gene co-expression network reconstruction
Corrected gene expression data were analysed using weighted gene
co-expression analysis (WGCNA).15,16 We constructed a signed
weighted co-expression network based on the matrix of pairwise
Pearson correlation coefficients, which were raised to a fixed
power (b=12) by the criteria described by Zhang & Horvath.16
Soft-thresholding results in a 563865638 dimensional weighted
adjacency matrix containing pairwise connection strengths.
Subsequently, a topological overlap measure is calculated based
on the number of shared neighbours. Modules were then defined
as branches of a hierarchical clustering tree using a dissimilarity
measure (1 – topological overlap). Each module is subsequently
assigned a colour. To define a representative module expression
profile for each module, we summarised the (standardised) gene
expression profiles of the module by their first principal
component. This statistic is referred to as the module eigengene:
it can be thought of as an average gene expression value for all
probes in a module per sample. In order to identify hub genes,
we calculated a connectivity measure (‘module membership’)
per probe by correlating expression values with the relevant
module eigengene. Probes with high module membership are
defined as ‘hub genes’ of their module.
Module eigengenes and phenotypes of interest
The module eigengenes were correlated to phenotype of interest
using a linear model.17 Participants were assigned a main
diagnosis of a particular disorder (controls, ASD, MDD, adult
ADHD, childhood ADHD, ADHD–ASD) v. all other participants.
We investigated the effect of possible covariates on the association
of module eigengenes with our phenotypes of interest. This led us
to correct for gender, RIN and RNA concentration. Medication
use defined as dichotomous measures of use of antidepressants
(n=73), stimulants (n=49), antipsychotics (n= 7), benzo-
diazepines (n=5) and mood stabilisers (n= 5) were investigated
as a possible covariate. Considering the nature of the sample
collection of the childhood ADHD–ASD and childhood ADHD
samples, analyses were repeated also including age as covariate,
allowing us to tease out diagnosis and age-specific effects. We used
a Bonferroni threshold for significance (the number of tests was
calculated as the number of modules6number of diagnoses62).
Characterisation of modules of interest
Modules of interest were tested for enrichment of blood cell type
lists using the userListEnrichment function in WGCNA package
with five as minimum number of genes in a pathway. This
function compares the number of overlapping genes to the
maximal possible overlap and applies Bonferroni correction.
Enrichment analyses were performed in WebGestalt using
Wikipathways database.18 In addition, we performed connectivity
mapping on selected modules to investigate overlap with drug-
induced gene expression changes through the LINCS/CMap data-
base (http://apps.lincscloud.org).19 We entered the gene content of
modules of interest as upregulated, resulting in a list of
compounds of which the application to cell lines results in a
similar gene expression pattern.
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Table 1 Sample characteristics
Diagnosis n % male Age (s.d.) RIN (s.d.) % medication-free
Controls 78 59 46 (15) 8.3 (0.4) 97
Autism spectrum disorder 51 90 29 (11) 8.5 (0.3) 61
Major depressive disorder 63 33 47 (9) 8.5 (0.4) 29
Adult attention-deficit hyperactivity disorder 93 77 32 (12) 8.5 (0.5) 63
Childhood attention-deficit hyperactivity disorder 17 100 10 (2) 8.6 (0.4) 29
Autism spectrum disorder–attention-deficit hyperactivity disorder 16 100 11 (2) 8.7 (0.3) 69
RIN, RNA integrity number.
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Genotype information and previous genome-wide
association study (GWAS) findings
For most individuals genotype data were available and after
quality control and imputation polygenic risk score analysis and
genetic pathway analysis was carried out to investigate the
relationship of genome-wide risk to disorder-specific gene expression
findings in this study (see online supplement, Supplements DS2–4
and Figs DS1 and DS2).
Results
The WGCNA on 318 participants and 5638 probes resulted in
seven gene co-expression modules, ranging from 2077 probes in
the turquoise module to 80 probes in the red module. The grey
module contains 675 probes not belonging to any other module,
representing background noise. The network dendrogram is given
in online Fig. DS3 and all probes and corresponding module
assignments in online Table DS1. The module eigengenes
representing a summary of all genes in a given module were
related to our traits of interest: participants with a main diagnosis
of a particular disorder (controls, ASD, MDD, adult ADHD,
childhood ADHD, ADHD–ASD) v. all other participants,
covarying for gender, RIN, concentration in one model and also
including age in a second model. This results in 7 phenotypes66
module eigengenes = 42 tests per model, therefore 84 tests in total
when considering both models. We applied a Bonferroni threshold
for significance of P =0.05/84 = 661074. Results for the first
model are listed in Table 2. We did not find significant gene
expression effects for the ASD and ADHD–ASD groups. In
addition, medication use (antidepressants, stimulants, anti-
psychotics, mood stabilisers or benzodiazepines) was not
significantly associated to any gene co-expression module (online
Fig. DS4).
The green and red immune modules are inversely
correlated to psychiatric disorders
The green (186 probes) and red module (80 probes) eigenvalue
estimates per individual correlated negatively with MDD and
positively with adult ADHD status (Table 2, Fig. 1). Even though
the MDD sample is female-dominated and the adult ADHD
sample male-dominated, gender was included as a covariate and
therefore does not fully account for this effect. Results also remain
significant after additional correction for age. Of the 93
individuals with ADHD, 7 had comorbid MDD. However, these
individuals still resembled the pattern of the adult ADHD group
more than the MDD group (online Fig. DS5). Wikipathways
enrichment analyses through WebGestalt reveal significant
enrichment for regulation of toll-like receptor signalling pathway
(eight genes, adjusted P= 0.02) in the green module. The red
module, however, is enriched for immune-related pathways: type
II interferon signalling (nine genes, adjusted P= 1.861076), type
III interferon signalling (three genes, adjusted P=461073).
Connectivity mapping (http://apps.lincscloud.org)19 revealed
200 compounds corresponding to upregulation of genes in the
green module, and 3273 to upregulation in the red module. This
implies that application of these compounds to cell lines results in
a similar gene expression profile as we find for adult ADHD, and
opposite to that for MDD. Among the compounds, there were
several tricyclic (amitriptyline, desipramine, nortriptyline,
protriptyline, trimipramine) and other (nefazodone, trazodone)
antidepressants. In addition, there are steroid-related drugs
(among others: betamethasone, cucurbitacin-I, sarmentogenin,
wortmannin, alcomethasone, alfadolone, altrenogest, androstanol,
beclamethasone, cortisone, corticosterone) and other inflammatory
drugs (celecoxib, diclofenac, prostraglandin). Full connectivity
mapping results are given in online Table DS2.
Figure 1 depicts gene significance (correlation between pheno-
type and module eigengene) for MDD and adult ADHD of the red
and green module content. Size and colour indicate module
membership, our definition of connectivity. Gene significance is
highly correlated with gene connectivity in the green (MDD:
r=70.45, P=1.7610710, adult ADHD: r=0.36, P=6.261077)
and red (MDD: r=70.43, P=5.961075, adult ADHD: r=0.45,
P=2.961075) modules, indicating that highly connected hub genes
generally show the strongest associations with the phenotypes. The
six main green hub genes are YY1, AAK1, PAK2, C20ORF94 (now
SLX4IP), PAPD5 and SPATA13. The expression of transcription
factor YY1 indeed shows one of the highest negative correlations
with MDD status, together with TMEM189–UBE2V1, PSMC1,
WDR82 and LOC730052 (now UBE2V1P2). M6PR, TPM3,
TOB1, ZNF364 (now RNF115) and RAD21 show highest positive
correlation with adult ADHD. For the red module, the hub genes
are the interferon genes IFIT3, IFI35 and XAF1, PARP14 and two
probes for UBE2L6. Of these, PARP14 is highly inversely correlated
to MDD and adult ADHD, as are MX1 and EIF2AK2. In addition,
two probes for STAT1 show high gene significance for MDD and
OAS2 for adult ADHD.
Turquoise module represents overlapping signatures
between psychiatric disorders
The turquoise module (2077 probes) is positively correlated with
both MDD and childhood ADHD status (Table 2). This effect
does not remain significant for childhood ADHD after correction
for age. Enrichment analyses reveal significant categories to be
cytoplasmic ribosomal proteins (69 genes, adjusted
P= 2.2610722), electron transport chain (45 genes, adjusted
P= 1061.678) and oxidative phosphorylation (25 genes, adjusted
P= 161073). The correlation between gene significance and
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Table 2 Significant module trait associationsa
t (P)
Module
Probes,
n Controls
Major
depressive
disorder
Adult attention-deficit
hyperactivity
disorder
Childhood
attention-deficit
hyperactivity disorder
Autism spectrum
disorder–attention-deficit
hyperactivity disorder
Autism
spectrum
disorder
Turquoise 2077 ns 4.4 (1.461075)b ns 4.0 (5.861075)b ns ns
Red 80 ns 74.3 (1.561075)c 4.3 (2.261075)b ns ns ns
Green 186 ns 75.8 (8.861079) c 4.8 (1.561076)b ns ns ns
Blue 1672 ns ns ns 74.0 (6.761075) c ns ns
ns, not significant.
a. Module eigengenes were tested for association with phenotypes of interest including gender, RNA Integrity Number RIN and RNA concentration as covariates.
b. Positive associations.
c. Negative associations.
Cross-disorder gene expression analysis
connectivity is r=70.48, P52.2610716 for childhood ADHD
and r=70.48, P52.2610716 for MDD. Major hub genes in this
module are ZRANB2, TMEM126B, RPL15, PCNP and SRP9. The
genes with highest MDD gene significance are LOC1001291,
ANXA1, RNF13, GMFG and H3F3B. For childhood ADHD these
are SUMO3, RPL22, UTP3, POLE3 and CCDC50.
Disorder-specific signature of the blue module
The blue module (1672) is negatively correlated to childhood
ADHD status (Table 2). This effect does not remain significant
after correction for age. Enrichment analyses reveal the following
significant Wikipathways: integrin-mediated cell adhesion (26
genes, adjusted P=861074), focal adhesion (35 genes, adjusted
P= 161073), prostate cancer (21 genes, adjusted P=661073)
and IL17 signalling pathway (13 genes, adjusted P=0.04). The
correlation between childhood ADHD gene significance and
connectivity is r=70.5, P52.2610716. Blue hub genes are
WAS, MOBKL2A, C15orf39, G6PD and GNAI2. Genes with highest
negative correlation to childhood ADHD disease status are TMUB2,
STAT5B, DENND3, CA4, FCGR3B.
Relationship gene expression signatures and previous
GWAS findings
We did not find enrichment of GWAS signal or association of the
module eigengenes with polygenic risk scores for the modules of
interest (online supplements DS2–4 and Figs DS1 and DS2).
Discussion
Main findings
This study of whole-blood gene expression of several psychiatric
disorders aimed to reveal overlapping gene expression patterns
and disorder-specific signatures. The WGCNA on 318 participants
revealed seven gene co-expression modules. Of these, two small
modules are inversely related to MDD and adult ADHD, the large
turquoise module is associated with both MDD and childhood
ADHD and finally, the blue module shows a disorder-specific
signature for childhood ADHD. No significant results were found
for the ASD, ADHD–ASD and control groups. Even though there
is some evidence for increased immune-related comorbidities in
ASD20,21 we do not find an immune gene expression signature
for these groups, as we do for MDD and adult ADHD.
Interpretation and comparison with findings from
other studies
Two small modules, red and green, are negatively correlated to
MDD status, but positively correlated to adult ADHD status.
GWAS on both disorders have not yielded genome-wide
significant hits to date.22,23 Previous literature about genetic
overlap between MDD and ADHD has yielded conflicting results,
reporting a genetic correlation between MDD and ADHD,11 but
no significant overlap in polygenic risk scores.10 A reason for these
205
(a)
(b)
0.0 0.1 0.2 0.3
Gene significance adult ADHD
0.4 0.5
0.0 –
70.1 –
70.2 –
70.3 –
70.4 –
0.1 –
0.0 –
70.1 –
70.2 –
70.3 –
70.2 70.1 0.0 0.1
Gene significance adult ADHD
0.2 0.3
SPATA13
PAPD5SK2 AAK1
RAD21
ZNF364
TOB1
TRM3 M6PR
C20ORF94
WDR82PSMC1
LOC730052
YY1
TMEM189-UBE2V1
XAF1 IFI16
PARP14
MX1
OAS2
EIF2AK2
UBE2L6
STAT1
STAT1
IFI35
UBE2L6
IFIT3
G
e
n
e
si
gn
ifi
ca
n
ce
M
D
D
G
e
n
e
si
gn
ifi
ca
n
ce
M
D
D
Fig. 1 Gene significance for adult attention-deficit hyperactivity disorder (ADHD) v. that of major depressive disorder (MDD) for the
(a) green and (b) red modules.
Size and hue of the circles indicate gene module membership (connectivity). Genes showing highest gene significance are named.
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discrepancies could be the lack of distinction between adult
ADHD and childhood ADHD in previous studies, which could
add to phenotypic heterogeneity.5 The group with childhood
ADHD may include individuals whose condition will become less
severe with age, whereas the adult group with ADHD contains
individuals whose condition is chronic. Another reason why we
chose to analyse participants with childhood and adult ADHD
in separate groups is because of anticipated biological hetero-
geneity between children and adults in the context of peripheral
gene expression. An explanation for our findings would be gender
differences in prevalence of MDD and adult ADHD, however,
analyses were corrected for gender and stratified analyses yielded
the same results (data not shown). We also performed a
correlation with the module eigengenes and an indicator of
current state of depression (Beck Depression Inventory24) within
participants, which did not show a significant association (data
not shown).
The green module shows enrichment for a cell signalling
category and harbours some interesting highly connected hub
genes that also show high gene significance, most notably, YY1,
WDR82 and AAK1. YY1 is a transcription factor involved in
many processes including transforming growth factor beta
(TGF-b) signalling, but has also shown to be active in histone
modification.25 In addition WDR82 (WD repeat domain 82) is part
of SET1A/SET1B histone H3K4 methyltransferase complexes,26
which genetic pathway analyses has shown to be strongly enriched
for association in MDD, bipolar disorder and schizophrenia.27
This implication of epigenetic processes provides a mechanism
by which environmental influences can exert their influence on
gene expression and thereby contribute to the pathology of
neuropsychiatric disorders.28,29 The green hub gene adaptor-
associated kinase 1 (AAK1) is of interest because it is a positive
regulator of the Notch pathway.30 This pathway is traditionally
implicated in cell-fate determination during development, but
has important function in tissue homeostasis and neuronal
plasticity later in life. In addition, it has been implicated to play
a role in immune functioning.31–33
Even though the immune system has not been implicated in
adult ADHD before, there are many studies on its association with
MDD although the relationship is still somewhat controversial.34
Expression differences in cytokines have been shown to differentiate
patients with MDD from ones with bipolar disorder and
controls35 and studies have shown regulation of the serotonin
receptor through cytokines and neurotrophins.36,37 Importantly,
cytokines and polymorphisms in interleukin genes have been
shown to predict antidepressant treatment response.38,39 The
majority of patients with MDD (70%) and a few (13%) of the
participants with adult ADHD in the current study were on
antidepressant medication although medication use did not
correlate significantly with any gene expression module. However,
connectivity mapping revealed that the upregulation of genes in
red and green modules as seen in our adult ADHD group
coincides with those seen in response to application of a number
of tricyclic antidepressants, indicated for the treatment of
depression and ADHD with comorbid depression. Results also
contained some anti-inflammatory drugs, converging with the
module enrichments for immune system genes. This could
support the hypothesis that anti-inflammatory drugs such as
non-steroidal anti-inflammatory drugs (NSAIDs) might have a
role in the treatment of MDD and, our data suggests, also ADHD.
Literature on the effects of NSAIDs in patients with MDD is,
however, mixed.40,41 Our results suggest potential drug repositioning
opportunities for NSAIDs for both MDD and ADHD.
Whereas MDD and adult ADHD showed opposite patterns of
gene expression changes (the green and red modules), we found
an overlapping gene expression signature between MDD and
childhood ADHD, in the form of the turquoise module. One
possible interpretation of this finding is that childhood ADHD
increases risk for developing MDD in later life.42 In order to fully
untangle this, we would need childhood diagnoses of ADHD in
the MDD cohort, but this was not available.
Finally, we find a disorder-specific signature of childhood
ADHD in the blue module, which is highly enriched for cell
signalling genes. There are two hub genes located on the
X-chromosome; G6PD and WAS. Even though we corrected for
gender in our analyses, the childhood ADHD group consisted
solely of males, which might explain downregulation of
X-chromosome genes, although the blue module is not enriched
for genes on sex chromosomes. The significance of the association
of childhood ADHD with the turquoise and blue modules
disappears when adding age as a covariate in the analyses, but
in the absence of a healthy child control group, age and childhood
ADHD cohort membership are highly correlated. However, the
fact that the childhood dual diagnosis ADHD–ASD group does
not show a correlation with these modules suggests that age
cannot fully explain these results.
We did not find enrichment of GWAS signal or association of
the module eigengenes with polygenic risk scores for the modules
of interest (online supplements DS2–4 and Figs DS1 and DS2).
This could indicate that the differences in gene expression are
driven by environmental rather than genetic factors or, perhaps,
that polygenic scores are not yet strong enough in disorders such
as MDD and ADHD. One possible known environmental
influence on gene expression is smoking. Even though we did
not have access to smoking behaviour for all participants, a
Fisher’s exact test of enrichment of smoking-related genes43 did
not reveal a significant enrichment for the modules of interest
(data not shown). Likewise, a sample-handling or collection effect
is unlikely because of initial batch correction and the fact that the
healthy controls were for the most part from the same project as
the participants with MDD and yet do not show an effect for the
relevant modules. In addition, the lack of genetic association
could also be the result of the initial GWAS results being
underpowered to detect variants associated with MDD, ADHD
and ASD.
Directions for further study
Future research could extend this study to include a broader
range of psychiatric disorders, such as psychotic disorders
(schizophrenia) and anxiety disorders (obsessive–compulsive
disorder, generalised anxiety disorder), in order to better
understand the genomic correlates of different syndromes.
However, our results have several limitations including power to
detect effects in relatively small samples and the reliance upon
cross-sectional study designs. Our findings in adult ADHD and
MDD will require replication and assessment in different study
designs to assess potential therapeutic applications. Also, in this
study we examined gene expression in blood but it will be
important to determine whether the pattern of results holds true
for brain tissue. In ASD, for instance, changes in the expression of
a number of genes has been reported to be altered in post-mortem
studies.44
In conclusion, in a study of gene expression in peripheral
blood of patients with psychiatric disorders and healthy controls,
we identified both cross-disorder and disorder-specific signatures
for adult ADHD and MDD. With the caveats discussed above, they
suggest new pathways contributing to distinct pathophysiology in
psychiatric disorders and shed light on potential shared genomic
risk factors.
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Edinburgh Hospitality
Sally Fox
In Forth Valley
we had an integrated
Dialectical Behaviour Therapy service
for Borderline Personality.
From the onset of diagnosis
I was hand-reared and geared
towards a ‘life worth living’.
Whilst giving me the skills to cope,
they held the hope for me
till I could hold it for myself.
My future felt bright
with The Capital in my sights.
I expected continuity of care
Clearly too much to dare!
My notes and referral were lost in transition
and consequent decisions were made
that my PTSD wasn’t ‘present’ enough
for a referral to The Rivers Centre
and it was ‘too risky’
to enter into psychotherapy.
So I’m waiting for an appointment
with the Primary Care Liaison team.
I’ve waited eighteen months.
Now I’m told the OT is off sick.
And I am sick to my core
with the constant closed doors
But I guess that’s Edinburgh hospitality:
You’ll have had your DB . . . T!
Selected by Femi Oyebode. From Stigma & Stones: Living with a Diagnosis of BPD, poems by Sally Fox & Jo McFarlane.
B Sally Fox. Reprinted with permission.
Through their collection Stigma & Stones, writers/performers/partners Sally Fox and Jo McFarlane seek to promote
understanding, improve treatment and reduce the stigma of living with a diagnosis of BPD.
The British Journal of Psychiatry (2016)
209, 208. doi: 10.1192/bjp.bp.116.181693
poems
by
doctors
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Data supplement to de Jong et al. Cross-disorder gene expression 
analysis: immune signatures and disorder-specific patterns. Br J 
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Supplement DS1 
Description of different projects 
DECC: Depression Case Control project 
From this project we included gene expression data of 63 MDD cases and 57 controls.  
The Depression Case-Control (DeCC) study is a case-control study that recruited 
unrelated patients from three clinical UK sites: London, Cardiff and Birmingham [1]. 
Subjects were identified from psychiatric clinics, hospitals and general medical 
practices and from volunteers responding to media advertisements. All participants 
experienced two or more episodes of major depression of at least moderate 
severity. The diagnosis of MDD was ascertained using the Schedules for Clinical 
Assessment in Neuropsychiatry (SCAN) [2] interview. Subjects were excluded if they 
or a first-degree relative ever fulfilled criteria for mania, hypomania or 
schizophrenia. The controls were screened for lifetime absence of any psychiatric 
disorder using a modified version of the Past History Schedule [3]. Participants were 
excluded if they, or a first-degree relative, ever fulfilled the criteria for depression or 
any other psychiatric disorder. Approval was obtained from the local research ethics 
committees/institutional research boards of all of the participating sites in U.K.: 
London, Cardiff and Birmingham and all individuals gave written informed consent 
[4]. 
 
ADHD: Attention-Deficit Hyperactivity Disorder project 
From this project we included gene expression data of 93 aADHD cases. 
From this project we included gene expression data of 93 ADHD cases comprising 
adults attending a National Adult ADHD Outpatient Clinic. Self-report and informant 
based versions of the Barkley Adult ADHD Rating Scale (BAARS-IV) [5] were used to 
measure ADHD symptoms. Consisting of 18 DSM-IV items related to inattention and 
hyperactivity–impulsivity, respondents indicated how frequently they experienced 
behaviours on a scale of 0 to 3 (never or rarely, sometimes, often, very often) during 
the past 6 months. Total scores were calculated for each symptom dimension. 
de Jong et al. Sup info 2 
Informant ratings were provided by a family member or close friend. Diagnosis was 
based on psychiatric interview and the Conners Adult ADHD Diagnostic Interview for 
DSM-IV (CAADID) completed by a psychiatrist and a community psychiatric nurse. 
The CAADID is a structured interview divided into Part I (Patient History 
Questionnaire) and Part II (Diagnostic Criteria Interview), which are administered 
separately. Each of the 18 items is scored “yes”, if the behavioural symptom is 
present often within the past 6 months and outcomes are total current ADHD 
symptom score, and separate totals for inattentive and hyperactive-impulsive 
symptom domains. Participants attending assessment appointments were consented 
by a member of the BRC Bioresource team following the receipt of an information 
sheet and a detailed explanation of the BRC Bioresource initiative. Ethical approval 
was granted by the National Research Ethics Committee, London (12/LO/07990). 
 
BioNed: Biomarkers for Childhood Neuropsychiatric Disorders project 
From this project we included gene expression data of 15 ASD_ADHD cases, 7 ASD 
cases, 17 cADHD cases and 7 controls. 
All participants were male with a clinical diagnosis of autism, atypical autism, 
Asperger’s syndrome and/or a diagnosis of combined type ADHD (or hyperkinetic 
disorder) made according to ICD-10 or DSM-IV (American Psychiatric Association, 
2000; World Health Organization, 2005). Exclusion criteria included any known 
comorbid medical condition such as Major Mood Disorder (including bipolar I and II); 
severe OCD, severe Generalised Anxiety Disorder, Conduct Disorder and genetic 
disorders (e.g. Fragile X Syndrome). Participants were also excluded if they had a 
diagnosis of epilepsy or had received a head injury/neurological insult that may 
affect cognitive functioning. Individuals who were taking psychotropic medication 
(except for stimulants in ADHD) and who had a Full-Scale IQ (FSIQ) less than 70 
measured using the Wechsler Abbreviated Scale of Intelligence (WASI, Wechsler, 
1999) were not included. Participants taking stimulant medication were included, 
but a 24-48 hour washout period was mandatory prior to testing. Upon recruitment, 
participants were assigned to one of three research groups (ASD, ADHD, ASD+ADHD) 
using a multi-source, multi-measure approach, taking into consideration clinical 
status of the patient a well as additional standardised psychological measures. The 
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Social Communication (SCQ; Rutter et al. 2003), the Autism Diagnostic Interview-
Revised (ADI-R; Lord et al. 1994), and the Autism Diagnostic Observation Schedule-
Generic (ADOS-G; Lord et al. 2000) were used for the assessment of  ASD cases. The 
Conners 3rd edition parent short form (Conners 3-PS; Conners 2008), the Parent 
Account of Childhood Symptoms (PACS; Taylor et al. 1991; Chen and Taylor 2006) 
were used to confirm ADHD cases. Comorbid ASD+ADHD cases were required to 
meet full research diagnostic criteria for both ASD and ADHD. The study protocol 
was approved by a medical ethics committee (NHS REC Ref: 08/H0803/161). Parental 
written consent was given before the experiment began. 
 
AIMS: Autism Interventions 
From this project we included gene expression data of 44 ASD cases and 14 controls. 
All participants were right handed (measured using The Edinburgh Handedness 
inventory [6] and native English speakers.  Exclusion criteria included; pre-existing 
medical conditions or complications (e.g. head trauma, epilepsy); use of medication 
affecting brain function; mental retardation; a history of major psychiatric disorder 
(e.g. psychosis); chromosomal abnormality (e.g. fragile X, Tuberous Sclerosis, VCFS); 
and any MRI contraindications.  Intellectual ability was assessed using the WASI [7]. 
All participants had an IQ greater than 70 (i.e. were within the high-functioning 
range of the autistic spectrum). For the autistic group, inclusion was based on a 
clinical diagnosis of autism using the International Statistical Classification of 
Diseases, 10th Revision (ICD-10) research criteria and confirmed using the ADI-R [8] 
(all cases reached ADI-R algorithm cut-offs in the domains of impaired reciprocal 
social interaction, communication, and repetitive behaviors and stereotyped 
patterns, although failure to reach cutoff in a single domain by 1 point was 
permitted). Current symptoms were assessed using the ADOS [9], but not used as an 
inclusion criterion. The study was given ethical approval by the National Research 
Ethics Committee, Suffolk, UK. All volunteers gave written informed consent. 
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Supplement DS2  
 Genotype data preprocessing 
The majority of subjects with gene expression (n=252, 80%) were also genotyped as 
part of their respective projects. The MDD project subjects (n=57 cases, n=54 
controls) were genotyped on the Illumina 610k BeadChip, the ASD (n=34 cases, 14 
controls) and ADHD_ASD (n=12 ADHD_ASD cases, n=7 ASD cases, n=1 cADHD case) 
on the Illumina HumanCoreExome BeadChip and ADHD (n=73 aADHD cases) on the 
Illumina OmniExpress BeadChip. All data were quality controlled separately in Plink 
v1.07 [10] using the same parameters (SNPs were excluded when missingness >1%, 
MAF <0.01 or HWE <0.00001. Individuals were excluded when missingness >1%). Sex 
and relatedness checks were carried out, in addition to Eigensoft analyses to confirm 
self-reported ethnicities [11]. When necessary SNP positions were lifted over from 
hg18 to hg19 build using UCSC LiftOver tool [12]. To eliminate between chip 
genotype coverage differences, we imputed all datasets to the 1000Genomes, 
Phase1.v3 (SHAPEIT, no singletons) using the Michigan Imputation Server 
(https://imputationserver.sph.umich.edu), utilizing SHAPEIT and Minimac software. 
Imputed data was merged and filtered for quality using R2>0.3 and MAF>0.01.  
 
 
Supplement DS3 
FORGE genetic pathway analysis 
We examined significance of gene expression modules as pathways in published 
GWAS. We used FORGE to combine p-values per gene and subsequently pathways 
[13]. To assess LD structure we used the 1000 Genomes data after liftover to hg19 
and pruned with a R2=0.9 threshold using Priority Pruner, prioritizing low p-value 
SNPs within the PGC cross disorder results [14]. For the Forge.pl run a maximum of 
100,000 permutations was set and the algorithm was run with a fuzzy border option 
(5’ 35kb, 3’ 10kb). Subsequent gsa.pl runs used the Z statistic (fixed after 
permutations) for each gene, or the raw SNP p-value case of only one SNP per gene. 
FORGE genetic pathway analysis did not reveal enrichment of MDD, ADHD or ASD 
GWAS signal for any of the modules. 
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 Polygenic Risk Scores and gene expression 
Genome-wide (excluding MHC region) Polygenic Risk Scores for ADHD, ASD and MDD 
were generated with PRSice software [15] using PGC cross-disorder p-values as 
training sets [14] with the exception of the MDD summary statistics, which we have 
used the leave-one-out scores excluding RADIANT (of which DECC subjects are part). 
Polygenic risk scores (PRS) for ADHD, ASD and MDD were calculated for a subset 
(n=252) of samples (Supplementary X and XI below) and we applied a t-test between 
each phenotype and all other subjects, except cADHD because of lack of samples. 
The significance threshold was set at p<0.05/25=0.002. The PRS did not differ 
significantly between groups for any of the disorders. None of the PRS were not 
significantly associated to any of the module eigengenes, and did not change original 
results when taken along as covariates.   
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Fig. DS1 
Polygenic Risk Score distributions 
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Fig. DS2  
Polygenic Risk Scores in different disorder groups  
Polygenic Risk Scores for ADHD (panel A), ASD (Panel B) and MDD (Panel C) were 
calculated for a subset of 252 samples using a p<0.1 cutoff.  
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Fig. DS3 
 WGCNA dendrogram. Network reconstruction identifies 7 distinct modules of co-
expressed genes in whole blood of 318 cross disorder subjects. The dendrogram was 
produced by average linkage hierarchical clustering of genes using topological 
overlap. Modules of co-expressed genes were assigned numbers corresponding to 
the branches indicated by the horizontal bar beneath the dendrogram. 
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Fig. DS4 Module Trait Correlations 
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Fig. DS5 Supplementary Information IV: Green and Red ME expression for aADHD, 
MDD and comorbid subjects 
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Separate tables 
Table DS1: Gene list & module assignments (.xlsx). 
Table DS2: Connectivity mapping results for Green and Red modules via 
LINCS/CMap database (http://apps.lincscloud.org) (.xlsx). 
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